Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibogaine - ATAI Life Sciences/DemeRx

Next Previous
Drug Profile

Ibogaine - ATAI Life Sciences/DemeRx

Alternative Names: DMX-1002; Ibogaine HCl - ATAI Life Sciences/DemeRx; Ibogaine hydrochloride - ATAI Life Sciences/DemeRx; IBX-210

Latest Information Update: 02 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ATAI Life Sciences; DemeRx
  • Developer ATAI Life Sciences
  • Class Antipsychotics; Drug withdrawal therapies; Ethers; Heterocyclic compounds with 4 or more rings; Indoles; Neuropsychotherapeutics; Rauwolfia alkaloids; Small molecules
  • Mechanism of Action Excitatory amino acid antagonists; NMDA receptor antagonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Opioid-related disorders

Most Recent Events

  • 28 Mar 2024 ATAI Life Sciences plans a phase I/IIa trial for Opioid related disorders in second half of 2024
  • 31 Dec 2023 ATAI Therapeutics has patent protection for Ibogaine in USA, Europe, Australia, Canada, and Hong Kong
  • 31 Dec 2023 Atai Therapeutics has patents pending for ibogaine in USA, Australia and South Africa

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top